Less than two months after closing a $100m series C round, the Dundee spinout has raised $225m in a series D led by SoftBank Vision Fund 2.

Lilly Asia Ventures co-led a $61.7m round for the endoscopy technology developer that was also backed by Medtronic.

Renal care provider InterWell Health and skincare product manufacturer Make Essence both raised approximately $46m while Salesforce-backed JazzHR agreed a merger.

Yale’s immunological and inflammatory disease therapy developer has filed for an offering with an $86.3m placeholder target.

Harvard's T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.

The Alphabet, Astellas, Novartis and WuXi AppTec-backed T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.

Alphabet and Merck Group could exit the immunological and inflammatory disease therapy developer in an offering with an $86.3m placeholder target.

Carlyle Group has agreed to pay $435m for the biologics research technology provider, which has raised $86m from investors including Novo.

China Medical System and a WuXi Biologics industry investment fund were among the participants in the antibody therapy developer's $69.3m series A round.

Based on research at MIT, LiquiGlide has brought its overall funding to $50m following a $13.5m round.